镰状细胞病(11)

世界临床医学·2011年6月 第5卷 第6期

Department of Paediatric Haematology, King’s College Hospital NHS Foundation Trust, King’s College London, London, UK (D C Rees FRCP); Kenya Medical Research Institute Centre for Geographic Medicine Research-Coast, Kilifi, Kenya (T N Williams PhD); Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK (T N Williams); and Pulmonary, Allergy and Critical Care Medicine and Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA, USA （Prof M T Gladwell MD）

Correspondence to: Dr David C Rees, Department of Paediatric Haematology, King’s College Hospital NHS Foundation Trust, Denmark Hill, King’s College London, London SE5 9RS, UK（e-mail: david.rees@kcl.ac.uk）

参 考 文 献

[1] Weatherall D, Hofman K, Rodgers G, et al. A case for developing North-South partnerships for research in sickle cell disease. Blood, 2005, 105: 921–23

[2] Herrick JB. Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia. Arch Intern Med, 1910, 6: 517–21

[3] Sydenstricker VP. Further observations on sickle cell anemia. J Am Med

Ass, 1924, 83: 12–15

[4] Graham GS. Case of sickle cell anaemia with necropsy. Arch Intern Med,

1924, 34: 778–800

[5] Pauling L, Itano HA, Singer SJ, et al. Sickle cell anemia, a molecular

disease. Science, 1949, 110: 543–48

[6] Watson J, Staham AW, Billelo FP. The significance of the paucity of sickle

cells in newborn negro infants. Am J Med Sci, 1948, 215: 419–23[7] Perutz MF, Liquori AM, Eirich F. X-ray and solubility studies of the

haemoglobin of sickle-cell anaemia patients. Nature, 1951, 167: 929–31[8] John AB, Ramlal A, Jackson H, et al. Prevention of pneumococcal

infection in children with homozygous sickle cell disease. BMJ, 1984, 26: 1567–70

[9] Gaston MH, Verter JL, Woods G, et al. Prophylaxis with oral penicillin in

children with sickle cell anemia. N Engl J Med, 1986, 314: 1593–99[10] Johnson FL, Look AT, Gockerman J, et al. Bone-marrow transplantation

in a patient with sickle-cell anemia. N Engl J Med, 1984, 311: 780–83[11] Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on

frequency of painful crises in sickle cell anemia. N Engl J Med, 1995, 332: 1317–22

[12] Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by

transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med, 1998, 339: 5–11[13] Nagel RL, Fabry ME, Steinberg MH. The paradox of hemoglobin SC disease. Blood Revn, 2003, 17: 167–78

[14] Serjeant GR, Serjeant BE. Sickle cell disease. Oxford, UK. Oxford

University Press, 2001

[15] Moo-Penn W, Bechtel K, Jue D, et al. The presence of hemoglobin S and

C Harlem in an individual in the United States. Blood, 1975, 46: 363–67[16] Monplaisir N, Merault G, Poyart C, et al. Hemoglobin S Antilles: a

variant with lower solubility than hemoglobin S and producing sickle cell disease in heterozygotes. Proc Natl Acad Sci USA, 1986, 83: 9363–67

[17] Witkowska HE, Lubin BH, Beuzard Y, et al. Sickle cell disease in

a patient with sickle cell trait and compound heterozygosity for hemoglobin S and hemoglobin Quebec-Chori. N Engl J Med, 1991, 325: 1150–54

[18] Nagel RL, Daar S, Romero JR, et al. HbS-Oman heterozygote: a new

dominant sickle syndrome. Blood, 1998, 92: 4375–82

460

[19] Masiello D, Heeney MM, Adewoye AH, et al. Hemoglobin SE disease—

a concise review. Am J Haematol, 2007, 82: 643–49

[20] Geva A, Clark JJ, Zhang Y, et al. Hemoglobin Jamaica Plain—a sickling

hemoglobin with reduced oxygen affi nity. N Engl J Med, 2004, 351: 1532–38

[21] Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J

Med, 1997, 337: 762–69

[22] Brittenham GM, Schechter AN, Noguchi CT. Hemoglobin S

polymerization: primary determinant of the hemolytic and clinical severity of the sickling syndromes. Blood, 1985, 65: 183–89

[23] Noguchi CT, Rodgers GP, Serjeant G, et al. Levels of fetal hemoglobin

necessary for treatment of sickle cell disease. N Engl J Med, 1988, 318: 96–99

[24] Frenette PS. Sickle cell vaso-occlusion: multistep and multicellular

paradigm. Curr Opin Hematol, 2002, 9: 101–06

[25] Turhan A, Weiss LA, Mohandas N, et al. Primary role for adherent

leukocytes in sickle cell vascular occlusion: a new paradigm. Proc Natl Acad Sci USA, 2002, 99: 3047–51

[26] Belcher JD, Bryant CJ, Nguyen J, et al. Transgenic sickle mice have

vascular inflammation. Blood, 2003, 101: 3953–59

[27] Osarogiagbon UR, Choong S, Belcher JD, et al. Reperfusion injury

pathophysiology in sickle transgenic mice. Blood, 2000, 96: 314–20[28] Wood KC, Hebbel RP, Granger DN. Endothelial cell NADPH oxidase

mediates the cerebral microvascular dysfunction in sickle cell transgenic mice. Faseb J, 2005, 19: 989–91

[29] Belcher JD, Mahaseth H, Welch TE, et al. Critical role of endothelial cell

activation in hypoxia-induced vasoocclusion in transgenic sickle mice. Am J Physiol Heart Circ Physiol, 2005, 288: H2715–25

[30] Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease.

Life expectancy and risk factors for early death. N Engl J Med, 1994, 330: 1639–44

[31] Pegelow CH, Colangelo L, Steinberg M, et al. Natural history of blood

pressure in sickle cell disease: risks for stroke and death associated with relative hypertension in sickle cell anemia. Am J Med, 1997, 102: 171–77

[32] Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular

accidents in sickle cell disease: rates and risk factors. Blood, 1998, 91: 288–94

[33] Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a

risk factor for death in patients with sickle cell disease. N Engl J Med, 2004, 350: 886–95

[34] Kato GJ, Hsieh M, Machado R, et al. Cerebrovascular disease associated

with sickle cell pulmonary hypertension. Am J Hematol, 2006, 81: 503–10

[35] Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease:

reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev, 2007, 21: 37–47

[36] De Castro LM, Jonassaint JC, Graham FL, et al. Pulmonary hypertension

associated with sickle cell disease: clinical and laboratory endpoints and disease outcomes. Am J Hematol, 2008, 83: 19–25

[37] Ataga KI, Moore CG, Jones S, et al. Pulmonary hypertension in patients

with sickle cell disease: a longitudinal study. Br J Haematol, 2006, 134: 109–15

[38] Dham N, Ensing G, Minniti C, et al. Prospective echocardiography

assessment of pulmonary hypertension and its potential etiologies in children with sickle cell disease. Am J Cardiol, 2009, 104: 713–20[39] Minniti CP, Sable C, Campbell A, et al. Elevated tricuspid regurgitant jet

百度搜索“77cn”或“免费范文网”即可找到本站免费阅读全部范文。收藏本站方便下次阅读，免费范文网，提供经典小说教育文库镰状细胞病(11)在线全文阅读。